Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Vaxart Inc. (NASDAQ: VXRT) shares traded higher Tuesday after a study titled "A Phase 2 Trial With an Oral Tableted Covid-19 Vaccine" was posted to Clinicaltrials.gov. This may have inspired retail traders to buy the stock.

What's Going On With Vaxart's Stock?

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?

SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, investigates potential claims on behalf of Vaxart, Inc. (NASDAQ: VXRT) against certain of its officers for violations of federal securities laws. If you are a current shareholder of Vaxart, holding shares before June 25, 2020 , you may have standing to hold Vaxart harmless from the alleged harm caused by the officers of the Company by making them personally responsible.

Did You Acquire (VXRT) Before June 25, 2020? Johnson Fistel Investigates Vaxart; Should Management be Held Accountable for Investors Losses?

CureVac B.V

Moderna

Novavax

Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. The post Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today appeared first on InvestorPlace.

Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today

BioNTech SE

Pfizer

Good news from Merck and Ridgeback caused these stocks to fall.

Why Pfizer, BioNTech, Novavax, and Vaxart Stocks Are Sinking Today

CRISPR Therapeutics

Nikola

Ocugen, Inc.

These companies could deliver jaw-dropping revenue growth through mid-decade.

4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years

The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19. The post Vaxart Traders Should Not Dismiss the Vaccine Maker's Momentum appeared first on InvestorPlace.

Vaxart Traders Should Not Dismiss the Vaccine Maker's Momentum

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced the appointment of James F.

Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and the 15th Vaccine Congress.

Vaxart To Present at Upcoming Vaccine Conferences

While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration. The post It's Time to Start Thinking Seriously About Vaxart appeared first on InvestorPlace.

It's Time to Start Thinking Seriously About Vaxart

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board.

Vaxart Announces Creation of Manufacturing and Quality Advisory Board

SOUTH SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m.

Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30

Blink Charging

Bionano Genomics

These under-the-radar companies are expected to deliver jaw-dropping revenue growth over the next four years.

4 Small-Cap Growth Stocks Expected to Increase Sales 707% to 9,406% by 2024

Here's Some Good News for Vaccine Stock Investors

Vaxart Inc. (NASDAQ: VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a technical pattern.

Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern

If you're looking to wager on a vaccine long-shot, place your bet on VXRT stock. The post Vaxart Stock Is One Vaccine Also-Ran Worth Another Look appeared first on InvestorPlace.

Vaxart Stock Is One Vaccine Also-Ran Worth Another Look

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2021 /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, and Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the H.C.

Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine), aiming to overcome needle challenges. The post Is Vaxart Stock Really Worth a Shot?

Is Vaxart Stock Really Worth a Shot?

Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained 22% since.

Longshot Covid Play Vaxart Stock Is Too Risky at These Prices

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M.

Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D.

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.

Vaxart Announces Creation of New Scientific and Clinical Advisory Board

VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares.

Vaxart Is Another Risky Biotech Stock to Avoid Right Now

Atea Pharmaceuticals

Johnson & Johnson

Merck

Sorrento Therapeutics Inc

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

The Delta Covid variant gives Vaxart new life with its oral vaccine and could boost VRXT stock. VXRT stock is worth over 30% more at $13.00 if its Covid pill works, according to sell-side analysts.

The Delta Variant Is a Shot in the Arm for Vaxart's Pill Vaccine

Vaxart's oral recombinant vaccines are an interesting approach. Whether they do anything for VXRT stock remains to be seen.

News for Vaxart Stock (VXRT)